Carnegie Investment Counsel Acquires 15,952 Shares of Johnson & Johnson (NYSE:JNJ)

Carnegie Investment Counsel raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 144,611 shares of the company's stock after acquiring an additional 15,952 shares during the quarter. Carnegie Investment Counsel's holdings in Johnson & Johnson were worth $22,339,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. MBA Advisors LLC grew its stake in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its stake in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the last quarter. Nabity Jensen Investment Management Inc grew its stake in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in Johnson & Johnson by 0.5% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company's stock valued at $2,151,000 after buying an additional 69 shares during the last quarter. Finally, Almanack Investment Partners LLC. grew its stake in Johnson & Johnson by 1.1% in the 1st quarter. Almanack Investment Partners LLC. now owns 6,633 shares of the company's stock valued at $1,100,000 after buying an additional 71 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.3%

NYSE JNJ traded up $0.52 on Thursday, hitting $169.62. The company's stock had a trading volume of 6,629,361 shares, compared to its average volume of 8,401,730. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company's 50-day moving average is $155.75 and its 200 day moving average is $155.63. The firm has a market cap of $408.11 billion, a PE ratio of 18.14, a PEG ratio of 2.15 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.07%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.